

CURRICULUM VITAE
David D. Dore, PharmD, PhD

CONTACT INFORMATION

Office: Exponent, Inc.
1075 Worcester Street
Natick, MA 01760
+1 508 654 5104
ddore@exponent.com

Home: 11 Hastings Court
Dartmouth, MA 02747

EDUCATION

- 2008 PhD, Epidemiology (Advisor: Kate L. Lapane, PhD)
Brown Medical School, Providence, RI
Dissertation: "Benefits and Consequences of Drug Therapy in the Elderly"
- 2006–2007 Post-doctoral Fellowship (Mentor: Vincent Mor, PhD)
Center for Gerontology and Health Care Research
Brown Medical School, Providence, RI
- 2004 PharmD (Doctor of Pharmacy)
University of Rhode Island, Kingston, RI

PRIMARY PROFESSIONAL APPOINTMENTS/AFFILIATIONS

- 2020–present Principal Scientist (Pharmacoepidemiologist)
Center for Health Sciences, Exponent, Inc.
Natick, MA 01760
- 2021–present Key Personnel and Technical Lead (through Exponent), Long Term
Care Data Cooperative. Funded by the National Institute on Aging via
the Impact Collaboratory (www.impactcollaboratory.org). PI: Vincent
Mor, PhD – Brown University School of Public Health. NIH Project
Number 3U54AG063546-02S6

ADDITIONAL PROFESSIONAL APPOINTMENTS

- 2022–present Adjunct Professor of Health Services, Policy & Practice
Brown University School of Public Health.
(Faculty appointments at Brown University continuous since 2008)

PREVIOUS PROFESSIONAL APPOINTMENTS/AFFILIATIONS

- 2014–2022 Adjunct Assistant Professor of Health Services, Policy & Practice
Brown University School of Public Health.

- 2019 Vice President, Health Services Research, UnitedHealth Group Corporate Research & Development
(Continuous employment at UHG/Optum from 2007–2019)
- 2017 – 2019 Chief Research Officer, Optum Analytics – Life Sciences
Responsibility to Several Business Units: Digital Research Network, Epidemiology, Health Economics and Outcomes Research, and Patient Insights. General Manager for Epidemiology, data engineering, and IT software development
- 2013–2018 Member, Data and Safety Monitoring Board, “Levonorgestrel Intrauterine System versus Combined Oral Contraceptives for Heavy Menses (1R01HD074751-01, NICHD)”. PI: Kristen A. Matteson, MD, MPH
- 2014–2017 Vice President of Epidemiology and Principal Epidemiologist, Optum
Included Profit and Loss Responsibility
- 2013–2017 Adjunct Assistant Professor of Health Care Leadership, Brown University
(Executive Master of Healthcare Leadership)
- 2012–2015 Investigator, Health Services, Research & Development Service
Providence Veterans Affairs Medical Center
- 2011–2014 Assistant Professor of Health Services, Policy, and Practice (tenure track)
Brown University School of Public Health
- 2011–2014 Assistant Professor of Epidemiology
Brown University School of Public Health
- 2011–2014 Faculty Investigator
Center for Gerontology and Health Care Research
Brown University School of Public Health
- 2011–2014 Senior Consultant, Epidemiology
Optum Epidemiology (formerly i3 Drug Safety/Innovus)
- 2010–2011 Senior Scientist
Optum Epidemiology (formerly i3 Drug Safety/Innovus), Waltham, MA
- 2007–2010 Epidemiologist III (Senior Epidemiologist)
i3 Drug Safety, Waltham, MA
- 2008–2011 Adjunct Assistant Professor of Community Health
Department of Community Health
The Warren Alpert Medical School of Brown University
Providence, RI
- 2007 Consultant, Pharmacoepidemiology
i3 Drug Safety, Waltham, MA

- 2006–2007 Consultant
Pfizer Safety and Risk Management, New London, CT
- 2006 Per Diem Staff Pharmacist
Stop and Shop Pharmacy, Rhode Island
- 2005–2006 Research Fellow in Pharmacoepidemiology and Therapeutic Risk
Management
Pfizer Safety and Risk Management, New London, CT
- 2004–2005 Floating Staff Pharmacist
Brooks-Eckerd Pharmacy (now Rite Aid), Rhode Island

COMMUNITY SERVICE

- 2013–2015 Alternate Member, Zoning Board of Appeals, Town of Dartmouth, MA
(appointed by Select Board)

HONORS AND AWARDS

- 2011 Team Member, Ingenix First Place Innovation Award—Ingenix (Optum) Natural
History of Disease Application
- 2010 Ingenix (Optum) President's Award Recipient
- 2006–2010 Annals of Internal Medicine Outstanding Reviewer Recognition
Reviews graded by editors to be in the top 10% of all peer reviews (multiple years)
- 2004 Rhode Island Pharmacists Association Student Service Award
- 2004 American Pharmacists Association Mortar and Pestle Professionalism Award
- 2004 University of Rhode Island College of Pharmacy Excellence in Research Award
- 2004 Kappa Psi Pharmaceutical Fraternity Brother of the Year Award
- 2002 Kappa Psi Pharmaceutical Fraternity Scholarship Honors

TEACHING EXPERIENCE

Courses

- 2014–2016 Co-instructor: EHML2030 "Data-Driven Decision Making: The Structure, Conduct,
Review, and Evaluation of Research," an online course offered as part of the Brown
Executive Master of Healthcare Leadership

- Spring 2013 Co-instructor: PHP2120 "Introduction to Epidemiologic Research Methods," a semester-long course offered as part of the Brown University-Pfizer Master of Arts Program in Biology
- 2012–2015 Lead Instructor: PHP2490 "Methods in Pharmacoepidemiology," a semester-long course for masters and doctoral students on advanced pharmacoepidemiologic methods. Brown University School of Public Health
- 2011–2013 Section Leader: PHP2507 "Introduction to Biostatistics," a semester-long analytic internship course for students in the Master of Public Health program. Brown University School of Public Health
- 2009–2015 Lead Instructor: PPH2440 "Introduction to Pharmacoepidemiology," a semester-long course for clinicians, master-degree students, and doctoral students in epidemiology and health services research covering topics related to studying outcomes of medical interventions. Brown University School of Public Health
- 2008–2012 Section Leader: Biol3650 C IMS-II, "Epidemiology/Quantitative Reasoning" 1st and 2nd year medical curriculum, Brown Medical School
- 2007 Guest Lecturer: PPH2410C "Pharmacoepidemiology" Program in Public Health, Brown Medical School
- 2006–2007 Guest Lecturer: PPH1700K "Health Policy Challenges" Department of Public Policy, Brown University

Special Training Received

- 2005 Teaching Certificate I
Brown University Sheridan Center for Teaching and Learning in Higher Education
Awarded after participation in the Sheridan Teaching Seminar lectures and workshops, participation in a departmental micro-teaching session, completion of an individual teaching consultation, and submission of a formal summary evaluation

Advising and Mentoring

- 2013–2017 Committee Chair, **Andrew Zullo, PharmD, PhD** (PhD, health services research). Title: "Use, safety, and effectiveness of diabetes medications in older nursing home residents." Department of Health Services, Policy, & Practice, Brown University School of Public Health (with Vincent Mor, PhD, Roe Gutman, PhD, and Robert J. Smith, MD)

Current Position: Associate Professor of Health Services, Policy and Practice (tenured) & Associate Professor of Epidemiology, Brown University School of Public Health

- 2013–2015 Committee Member, **Kevin Fain, JD, MPH, DrPH** (DrPH, epidemiology). Title: "Prescription Opioid Use in Elderly Nursing Home Residents." Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health. (with Carlos Castillo-Salgado, MD, JD, MPH, DrPH [Chair], Jodi Segal, MD, MPH, and G. Caleb Alexander, MD, MS)

Current Position: Senior Policy Advisor, Office of New Drug Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

2013–2014 Primary Thesis Advisor, **Wei Lu, PhD, MPH**. Brown University Master of Public Health Program. Title: “Persistence on Treatment with GLP-1 Receptor Agonists and DPP-4 Inhibitors in Type 2 Diabetes Mellitus” (with Ira Wilson, MD, MSc)

2013–2014 Primary Thesis Advisor, **Catherine Rogers Murray, MPH**. Brown University Master of Public Health Program. Title: “Pediatricians and Parents’ Vaccine Hesitancy—An Exploration of Processes in Rhode Island” (with Melissa Clark, PhD)

Current Position: Managing Scientist, Center for Health Sciences, Exponent, Inc.

2012–2014 Committee Member, **Valery Danilack** (PhD, epidemiology). Title: “Understanding the Effect of Labor Induction on the Risk of Cesarean Delivery” Department of Epidemiology, Brown University School of Public Health. (with David Savitz, PhD [chair], Elizabeth Triche, PhD, and Maureen Phipps, MD, MPH)

Current Position: Associate Research Scientist, Yale University School of Medicine

2012–2014 Primary Thesis Advisor, **Katie Haron, MPH**. Brown University Master of Public Health Program. Title: “Case-crossover study of ADHD treatments and occurrence of migraine” (with Joseph Braun, MPSH, PhD)

2012–2014 Committee Member, **Michael Lopez, PhD** (PhD, biostatistics). Title: “Treatment choice for aging population: Causal inference with multiple treatments.” Department of Biostatistics, Brown University School of Public Health (with Roege Gutman, PhD [chair], Joseph Hogan, ScD, and Vincent Mor, PhD)

Awarded: Ruth L. Kirschstein National Research Service Awards for Individual Pre-doctoral Fellows (Parent F31)

Current Position: Senior Director of Data and Analytics at National Football League

2012–2014 Committee Member, **Nina Joyce, PhD** (PhD, epidemiology). Department of Epidemiology, Brown University School of Public Health (with Greg Wellenius, ScD [chair] and Justin Zachariah, MD, MPH)

Awarded: American Heart Association Pre-doctoral Fellowship

Current Position: Assistant Professor of Epidemiology, Brown University School of Public Health

2012–2014 Primary advisor for cohort of MPH students, Brown University Master of Public Health Program

2012–2013 Primary Thesis Advisor, **Efstathios Michalopoulos, MPH**. Brown University Master of Public Health Program. Title: “Prescription Patterns and Costs Associated with Treatment of Acute Depressive Episodes and Manic Episodes Associated with Bipolar-I Disorder (BD-1) Among Commercially Insured Patients.” Brown University School of Public Health (with Amal Trivedi, MD, MPH and Brady Case, MD)

Current Position: Associate Director, Health Economics & Outcomes Research, Vertex Pharmaceuticals

2011–2013 Committee Chair, **Danya Qato, PharmD, MPH, PhD** (PhD, health services research). Title: “Elucidating the Role of Patients, Providers, and Policies in Predicting (mis)Use of High-Risk Prescription Medications.” Department of Health Services, Policy, & Practice, Brown University School of Public Health. (with Amal Trivedi, MD, MPH and Vincent Mor, PhD)

Awarded: Fullbright Scholarship, 2015 – 2016

Current Position: Associate Professor and Graduate Program Director, University of Maryland, Baltimore

2011–2014 Committee Chair, **Kade Etter, PhD** (PhD, health services research). Title: “The Effect Device Characteristics on the Rate of Total Hip and Knee Replacement Revisions in the Veterans Administration (VA) Healthcare System.” Department of Health Services, Policy, & Practice, Brown University School of Public Health (with Ira Wilson, MD, MSc, Linda Resnik, PT, PhD, Art Sedrakyan, MD, PhD, and Roe Gutman, PhD)

Awarded: AHRQ Dissertation Grant

Current Position: Associate Director of Healthcare Analytics, Health Economics & Market Access at Johnson & Johnson Medical Devices

2011–2012 Committee Member, **Alicia Cooper, PhD** (PhD, health services research). Title: “Predictors and consequences of inappropriate drug prescribing among the elderly.” Department of Health Services, Policy, & Practice, Brown University. (with Amal Trivedi, MD, MPH [chair], Lewis Kazis, ScD, and Vincent Mor, PhD)

Winner: AcademyHealth's Outstanding Dissertation Award, 2013

Current Position: Health Care Project Director - Payment Reform at Department of Vermont Health Access

2009–2011 Committee Member, **Shirley V. Wang, PhD** (PhD, epidemiology). Title: “Evaluating the role of antipsychotic use as a trigger for ischemic stroke: application and extension of self-controlled designs.” Department of Community Health, Brown University. (with Stephen Buka, ScD [chair], Crystal Linkletter, PhD, Vincent Mor, PhD, and Malcolm Maclure, ScD)

Current Position: Associate Professor, Harvard Medical School/Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital

PROFESSIONAL LICENSE

2004–2020 Registered Pharmacist, Rhode Island (RPH04437)

ACADEMIC SERVICE AND PROFESSIONAL AFFILIATIONS

- 2022–present Member, Real-world Evidence | Learning Healthcare System Workstream. Duke-Margolis Center for Health Policy.
(Appointed representative of the International Society for Pharmacoepidemiology)
- 2018–2021 Member, Expert Advisory Panel, “Observational Patient Evidence for Regulatory Approval and uNderstanding Disease (OPERAND).” Led by OptumLabs & The Multi-regional Clinical Trials Center (MRCT) of Brigham and Women’s Hospital and Harvard Medical School
- 2017–2020 Member, North American Regional Advisory Committee, Drug Information Association
- 2017 Workgroup Member, “State of the Science for Pragmatic Trials of Non-Pharmacological Interventions to Improve Outcomes Among Persons with Dementia and Their Caregivers.” National Institute on Aging, Bethesda, Maryland
- 2016 Panelist, “Real-World Evidence Generation and Evaluation of Therapeutics: A Workshop.” The National Academy of Sciences, Engineering, and Medicine (Institute of Medicine). Washington, DC
- 2015 Workgroup Member, “Data Quality and Missing Data in Patient-Centered Outcomes Research Using EMR/Claims Data.” Patient-centered Outcomes Research Institute (PCORI). Washington, DC
- 2014–present Member, International Society for Pharmacoconomics and Outcomes Research
- 2014–2017 Professional Member, American Diabetes Association
- 2013–2014 Member, American Association for the Advancement of Science
- 2012–2013 Member, Association of Rheumatology Health Professionals
- 2011 Member, Special Emphasis Panel for review of pilot project grant applications for the Patient-centered Outcomes Research Institute (PCORI)
- 2011 Member, Faculty Search Committee. Department of Health Services, Policy, & Practice, Brown University
- 2011–2013 Member, Admissions Committee Brown University Doctoral Program in Health Services Research
- 2007 Proposal Reviewer: Health, Welfare, and Food Bureau. The People’s Republic of China (Hong Kong Administrative Region).
- 2006–2007 Member, American Public Health Association
- 2006–2008 Member, AcademyHealth

- 2005–present Member, International Society for Pharmacoepidemiology (ISPE);
Specific Roles:
- Member, Finance, Membership and Public Policy Committees (2021–present)
 - Co-chair, Local Host Committee (2015)
 - Member, Scientific Program Committee (2015)
 - Education Committee (2010–2013)
 - Development Committee (2007–2009)
 - 25th Anniversary Committee (2008–2009)
 - Local Host Committee for ICPE 2009 (2008–2009)
 - Abstract Reviewer (2008–Present)
- 2004–2008 Member, Kappa Psi Pharmaceutical Fraternity Graduate Chapter, Providence, RI

PEER REVIEWER (selected journals)

Journal of the American Medical Association (JAMA)
 PLOS One
 Current Medical Research and Opinion
 Medical Care
 American Journal of Epidemiology
 British Medical Journal (BMJ)
 Journal of Clinical Epidemiology
 Effective Health Care Program of the Agency for Healthcare Research and Quality (AHRQ)
 Medicare & Medicaid Research Review
 Epidemiology
 Diabetes, Obesity, and Metabolism
 Diabetologia
 Journal of the European Academy of Dermatology and Venereology
 Pharmacoepidemiology and Drug Safety
 FDA Mini-Sentinel Project
 Annals of Internal Medicine
 JAMA Internal Medicine (Archives of Internal Medicine)
 Diabetes Research and Clinical Practice
 Journal of Diabetes Science and Technology
 Movement Disorders
 Clinical Therapeutics
 Journal of Managed Care Pharmacy
 American Journal of Geriatric Pharmacotherapy
 Annals of Pharmacotherapy
 the Journal of Pharmacy Technology

REFEREED PUBLICATIONS

1. Zullo AR, Duprey MS, Smith RJ, Gutman R, Berry SD, Munshi MN, **Dore DD**. Effects of dipeptidyl peptidase-4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents. *Diabetes Obes Metab.* 2022;24(2):247-256. doi:

10.1111/dom.14573. PMID: 34647409

2. Zullo AR, Smith RJ, Gutman R, Kohler B, Duprey MS, Berry SD, Munshi MN, **Dore DD**. Comparative safety of dipeptidyl peptidase-4 inhibitors and sulfonylureas among frail older adults. *J Am Geriatr Soc*. 2021;69(10):2923-2930. doi: 10.1111/jgs.17371. PMID: 34291453; PMCID: PMC8497422
3. Funch D, Mortimer K, Ziyadeh NJ, Seeger JD, Zhou L, Ng E, Ross DS, Major-Pedersen A, Bosch-Traberg H, Gydesen H, **Dore DD**. Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population. *Diabetes Metab Syndr Obes*. 2021;14 2619–2629. doi: 10.2147/DMSO.S305496
4. Danilack VA, Hutcheon JA, Triche EW, **Dore DD**, Muri JH, Phipps MG, Savitz DA. Development and Validation of a Risk Prediction Model for Cesarean Delivery After Labor Induction. *J Womens Health (Larchmt)*. 2020;29(5):656-669. doi: 10.1089/jwh.2019.7822. PMID: 31657668
5. Funch D, Mortimer K, Ziyadeh NJ, Seeger JD, Li L, Norman H, Major-Pedersen A, Bosch-Traberg H, Gydesen H, **Dore DD**. Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population. *Diabetes Obes Metab*. 2019;21(8):1837-1848. doi: 10.1111/dom.13739. PMID:30945402; PMCID: PMC6772183
6. Liang C, Bertoia ML, Ding Y, Clifford CR, Qiao Q, Gagne JJ, **Dore DD**. Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study. *Diabetes Obes Metab*. 2019;21(4):1037-1042. doi: 10.1111/dom.13597. PMID: 30474347
7. Funch D, Mortimer K, Li L, Norman H, Major-Pedersen A, Olsen AH, Kaloft MS, **Dore DD**. Is there an Association between Liraglutide Use and Female Breast Cancer in a Real World Setting? *Diabetes Metab Syndr Obes*. 2018;11:791-806. doi: 10.2147/DMSO.S171503. PMID: 30538516
8. Zullo AR, Hersey M, Lee Y, Sharmin S, Bosco E, Daiello LA, Shah NR, Mor V, Boscardin WJ, Berard-Collins CM, **Dore DD**, Steinman MA. Outcomes of "diabetes-friendly" vs "diabetes unfriendly" β -blockers in older nursing home residents with diabetes after acute myocardial infarction. *Diabetes Obes Metab*. 2018;20(12):2724-2732. doi: 10.1111/dom.13451. PMID: 29952104
9. Loughlin AM, Qiao Q, Nunes AP, Ezzy SM, Yochum L, Clifford CR, Gately RV, **Dore DD**, Seeger JD. Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States. *Diabetes Spectr*. 2018;31(2):129-137. doi: 10.2337/ds16-0081. PMID: 29773932; PMCID: PMC5951230
10. Wang FT, Xue F, Ding Y, Ng E, Critchlow CW, **Dore DD**. Predictive values of diagnostic codes for identifying serious hypocalcemia and dermatologic adverse events among women with postmenopausal osteoporosis in a commercial health plan database. *BMC Health Serv Res*. 2018;18(1):263. doi:10.1186/s12913-018-3016-y. PMID: 29631582; PMCID: PMC5891890
11. Hoffman V, Abu-Elyazeed R, Enger C, Esposito DB, Doherty MC, Quinlan SC, Skerry K, Holick CN, Basile P, Friedland LR, Praet N, Wéry S, Willame C, **Dore DD**, Rosillon D. Safety study of live, oral human rotavirus vaccine: A cohort study in United States health insurance

- plans. *Hum Vaccin Immunother*. 2018;14(7):1782-1790. doi: 10.1080/21645515.2018.1450123. PMID: 29533129; PMCID: PMC6067866
12. Loughlin AM, Qiao Q, Nunes AP, Öhman P, Ezzy S, Yochum L, Clifford CR, Gately R, **Dore DD**, Seeger JD. Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States. *Diabetes Obes Metab*. 2018;20(4):898-909. doi: 10.1111/dom.13175. PMID: 29193561; PMCID: PMC5873410
 13. **Dore DD**, Zullo AR, Mor V, Lee Y, Berry SD. Age, Sex, and Dose Effects of Nonbenzodiazepine Hypnotics on Hip Fracture in Nursing Home Residents. *J Am Med Dir Assoc*. 2018;19(4):328-332.e2. doi: 10.1016/j.jamda.2017.09.015. PMID: 29126858; PMCID: PMC5871542
 14. Zullo AR, Sharmin S, Lee Y, Daiello LA, Shah NR, John Boscardin W, **Dore DD**, Lee SJ, Steinman MA. Secondary Prevention Medication Use After Myocardial Infarction in U.S. Nursing Home Residents. *J Am Geriatr Soc*. 2017;65(11):2397-2404. doi: 10.1111/jgs.15144. PMID: 29044457; PMCID: PMC5683399
 15. Nunes AP, Loughlin AM, Qiao Q, Ezzy SM, Yochum L, Clifford CR, Gately RV, **Dore DD**, Seeger JD. Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care. *Diabetes Ther*. 2017;8(6):1349-1364. doi: 10.1007/s13300-017-0314-z. PMID: 28983857; PMCID: PMC5688980
 16. Zullo AR, **Dore DD**, Gutman R, Mor V, Alvarez CA, Smith RJ. Metformin Safety Warnings and Diabetes Drug Prescribing Patterns for Older Nursing Home Residents. *J Am Med Dir Assoc*. 2017;18(10):879-884.e7. doi:10.1016/j.jamda.2017.05.020. PMID: 28676291; PMCID: PMC5612829
 17. Nunes AP, Iglay K, Radican L, Engel SS, Yang J, Doherty MC, **Dore DD**. Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. *Diabetes Obes Metab*. 2017;19(10):1425-1435. doi: 10.1111/dom.13000. PMID: 28497592
 18. Funch D, Ross D, Gardstein BM, Norman HS, Sanders LA, Major-Pedersen A, Gydesen H, **Dore DD**. Performance of claims-based algorithms for identifying incident thyroid cancer in commercial health plan enrollees receiving antidiabetic drug therapies. *BMC Health Serv Res*. 2017;17(1):330. doi:10.1186/s12913-017-2259-3. PMID: 28476125; PMCID: PMC5420112
 19. Steinman MA, Zullo AR, Lee Y, Daiello LA, Boscardin WJ, **Dore DD**, Gan S, Fung K, Lee SJ, Komaiko KDR, Mor V. Association of β -Blockers With Functional Outcomes, Death, and Rehospitalization in Older Nursing Home Residents After Acute Myocardial Infarction. *JAMA Intern Med*. 2017;177(2):254-262. doi: 10.1001/jamainternmed.2016.7701. PMID: 27942713
 20. Nunes AP, Yang J, Radican L, Engel SS, Kurtyka K, Tunceli K, Yu S, Iglay K, Doherty MC, **Dore DD**. Assessing Occurrence of Hypoglycemia and its Severity from Electronic Health Records of Patients with Type 2 Diabetes Mellitus. *Diabetes Res Clin Pract*. 2016;121:192-203. doi: 10.1016/j.diabres.2016.09.012
 21. Zullo AR, Lee Y, Daiello L, **Dore DD**, Mor V, Boscardin WJ, Miao Y, Fung K, Komaiko K, Steinman MA. Beta-Blocker Use Among United States Nursing Home Residents After

- Myocardial Infarction: A National Study. *J Am Geriatr Soc.* 2017;65(4):754-762. doi: 10.1111/jgs.14671. PMID: 27861719
22. Fain KM, Castillo-Salgado C, **Dore DD**, Segal JB, Zullo AR, Alexander GC. Inappropriate Fentanyl Prescribing Among Nursing Home Residents in the United States. *J Am Med Dir Assoc.* 2017;18(2):138-144. doi: 10.1016/j.jamda.2016.08.015. PMID: 27720662
 23. Fain KM, Alexander GC, **Dore DD**, Segal JB, Zullo AR, Castillo-Salgado C. Frequency and Predictors of Analgesic Prescribing in U.S. Nursing Home Residents with Persistent Pain. *J Am Geriatr Soc.* 2017;65(2):286-293. doi: 10.1111/jgs.14512. PMID: 28198563
 24. Zullo AR, **Dore DD**, Gutman R, Mor V, Alvarez C, Smith RJ. National Glucose-lowering Treatment Complexity is Greater among Nursing Home Residents than Community-dwelling Adults. *J Am Geriatr Soc.* 2016 Nov;64(11):e233-e235. doi: 10.1111/jgs.14485. PMID: 27677102
 25. Hoffman V, Everage NJ, Quinlan SC, Skerry K, Esposito D, Praet N, Rosillon D, Holick CN, **Dore DD**. Validation of current procedural terminology codes for rotavirus vaccination among infants in two commercially insured US populations. *Pharmacoepidemiol Drug Saf.* 2016;25(12):1465-1469. doi: 10.1002/pds.4085. PMID: 27623759
 26. Danilack VA, Triche EW, **Dore DD**, Muri JH, Phipps MG, Savitz DA. Comparing expectant management and spontaneous labor approaches in studying the effect of labor induction on cesarean delivery. *Ann Epidemiol.* 2016 Jun;26(6):405-411.e1. doi: 10.1016/j.annepidem.2016.04.009
 27. Genberg BL, Rogers WH, Lee Y, Qato DM, **Dore DD**, Hutchins DS, Brennan T, Matlin OS, Wilson IB. Prescriber and pharmacy variation in patient adherence to five medication classes measured using implementation during persistent episodes. *Pharmacoepidemiol Drug Saf.* 2016;25(7):790-7. doi: 10.1002/pds.4025. PMID: 27174150
 28. Zullo AR, **Dore DD**, Daiello L, Baier RR, Gutman R, Gifford DR, Smith RJ. National Trends in Treatment Initiation for with Diabetes Mellitus, 2008-2010. *J Am Med Dir Assoc.* 2016;17(7):602-8. doi: 10.1016/j.jamda.2016.02.023
 29. Qato DM, Trivedi A, Mor V, **Dore DD**. Disparities in Discontinuing Rosiglitazone Following the 2007 FDA Safety Alert. *Med Care.* 2016;54(4):406-13. doi: 10.1097/MLR.0000000000000502
 30. Liang C, Seeger JD, **Dore DD**. Implications of immortal person-time when outcomes are nonfatal. *Ann Epidemiol.* 2016;26(3):212-7. doi: 10.1016/j.annepidem.2015.12.004
 31. Lin ND, Norman H, Regev A, Perahia DG, Li H, Chang CL, **Dore DD**. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database. *BMC Gastroenterol.* 2015;15:134. doi: 10.1186/s12876-015-0373-4
 32. Danilack VA, **Dore DD**, Triche EW, Muri JH, Phipps MG, Savitz DA. The effect of labour induction on the risk of caesarean delivery: using propensity scores to control confounding by indication. *BJOG.* 2016;123(9):1521-9. doi: 10.1111/1471-0528.13682. PMID: 26411752
 33. Joyce N, Wellenius GA, **Dore DD**, Newburger JW, Zachariah JP. Patterns of Lipid Lowering Therapy among Children Ages 8-20 Years. *J Pediatr.* 2015;167(1):113-9.e1. doi:

10.1016/j.jpeds.2015.04.004

34. Zullo AR, **Dore DD**, Galarraga O. Development and validation of an index to predict personal prescription drug importation by adults in the United States. *J Pharma Health Serv Res.* 2015;6(1):33-41. doi: 10.1111/jphs.12088
35. Cooper AL, **Dore DD**, Kazis LE, Mor V, Trivedi AN. Predictors of high-risk prescribing among elderly Medicare Advantage beneficiaries. *Am J Manag Care.* 2014;20(10):e469-78
36. **Dore DD**, Ziyadeh N, Cai B, Clifford CR, Norman H, Seeger JD. A cross-sectional study of the identification of prevalent asthma and chronic obstructive pulmonary disease among initiators of long-acting β -agonists in health insurance claims data. *BMC Pulm Med.* 2014;14:47. doi: 10.1186/1471-2466-14-47
37. Cooper AL, Kazis LE, **Dore DD**, Mor V, Trivedi AN. Underreporting high-risk prescribing among Medicare Advantage plans: a cross-sectional analysis. *Ann Intern Med.* 2013;159(7):456-62. doi: 10.7326/0003-4819-159-7-201310010-00005
38. **Dore DD**. A Day in the Life of a Corporate Retail Pharmacist. *Ann Intern Med.* 2013;159(5):366-7. doi: 10.7326/0003-4819-159-5-201309030-00014
39. **Dore DD**, Hussein M, Hoffman C, Pelletier EM, Smith DB, Seeger JD. A pooled analysis of exenatide use and risk of acute pancreatitis. *Curr Med Res Opin.* 2013;29(12):1577-86. doi: 10.1185/03007995.2013.838550
40. **Dore DD**, Swaminathan S, Gutman R, Trivedi AN, Mor V. Erythropoietin-Stimulating Agents and Survival in End-Stage Renal Disease: Comparison of Payment Policy Analysis, Instrumental Variables, and Multiple Imputation of Potential Outcomes. *J Clin Epidemiol.* 2013;66(8 Suppl):S42-50. doi: 10.1016/j.jclinepi.2013.02.014. PMID: 477676
41. Berry SD, Lee Y, Cai S, **Dore DD**. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. *JAMA Intern Med.* 2013;173(9):754-61. doi: 10.1001/jamainternmed.2013.3795
42. **Dore DD**, Seeger JD, Chan KA. Incidence of Health Insurance Claims for Thyroid Neoplasm and Pancreatic Malignancy in Association with Exenatide Twice Daily: Signal Refinement Using Active Safety Surveillance. *Ther Adv Drug Saf.* 2012;3(4):157-164. DOI: 10.1177/2042098612446473
43. **Dore DD**, Liang C, Ziyadeh N, Norman H, Bayliss M, Seeger JD. Linkage of Routinely Collected Oncology Clinical Data with Health Insurance Claims Data—An Example with Aromatase Inhibitors, Tamoxifen, and All-Cause Mortality. *Pharmacoepidemiol Drug Saf.* 2012;21 Suppl 2:29-36. doi: 10.1002/pds.3244
44. **Dore DD**, Turnbull BR, Seeger JD. Vaccine Discontinuation and Switching Following Regulatory Interventions in Response to Rotavirus Vaccine Contamination with Porcine Circovirus DNA Fragments. *Pharmacoepidemiol Drug Saf.* 2012;21(4):415-9. doi: 10.1002/pds.3217
45. Wang S, Linkletter C, **Dore D**, Mor V, Buka S, Maclure M. Age, antipsychotics, and risk of ischemic stroke in the Veteran's Health Administration (VHA). *Stroke.* 2012;43(1):28-31

46. Wang SV, Linkletter C, Maclure M, **Dore DD**, Mor V, Buka SL, Wellenius GA. Future cases as present controls to adjust for exposure-trend bias in case-only studies. *Epidemiol.* 2011;22(4):567-573
47. **Dore DD**, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, Braun DK, Noel RA, Seeger JD. A Cohort Study of Acute Pancreatitis in Relation to Exenatide Use. *Diabetes Obes Metab.* 2011;13(6):559-66. doi: 10.1111/j.1463-1326.2011.01376.x
48. **Dore DD**, Chaudhry S, Hoffman C, Seeger JD. Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus. *Pharmacoepidemiol Drug Saf.* 2011;20(2):209-13. doi: 10.1002/pds.2077
49. **Dore DD**, Norman H, Loughlin J, Seeger JD. Extended Case-Control Study Results on Thromboembolic Outcomes among Transdermal Contraceptive Users. *Contraception.* 2010;81(5):408-413
50. **Dore DD**, Trivedi AN, Mor V, Friedman JH, Lapane KL. Atypical Antipsychotic Use and Risk of Fracture in Persons with Parkinson's Disease. *Mov Disord.* 2009;24(13):1941-1948
51. **Dore DD**, Trivedi AN, Mor V, Lapane KL. Association Between Extent of Thiazolidinedione Exposure and Risk of Acute Myocardial Infarction. *Pharmacotherapy.* 2009;29(7):775-783
52. Dosa DM, **Dore DD**, Mor V, Teno JM. Frequency of Long-Acting Opioid Analgesic Initiation in Opioid-Naïve Nursing Home Residents. *J Pain Symptom Manage.* 2009;38(4):515-521
53. Daiello L, Ott, B, Lapane KL, Reinert S, Machan JT, **Dore DD**. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. *Am J Geriatr Pharmacother.* 2009;7(2):74-83
54. **Dore DD**, Seeger JD, Chan KA. Use of a Claims-Based Active Drug Safety Surveillance System to Assess the Risk of Acute Pancreatitis with Exenatide or Sitagliptin Compared to Metformin or Glyburide. *Curr Med Res Opin.* 2009;25(4):1019-1027
55. **Dore DD**, Lapane KL, Trivedi AN, Mor V, Weinstock MA. Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial. *Ann Intern Med.* 2009;150(1):9-18
56. Lapane KL, Quilliam BJ, **Dore DD**. Roadblock on the Health IT Superhighway: E-Prescribing and the Controlled Substances Act. *J Opioid Manag.* 2007;3(4):181-184
57. **Dore DD**, DiBello JR, Lapane KL. Telithromycin Use and Spontaneous Reports of Hepatotoxicity. *Drug Saf* 2007;30(8):697-703
58. Caron MF, **Dore DD**, Min B, Kluger J, Boguk I, White CM. The Electrocardiographic and Blood Pressure Effects of the Ephedra Containing TrimSpa Thermogenic Herbal Compound in Healthy Volunteers. *Pharmacotherapy* 2006;26(9):1241-1246
59. **Dore DD**, Larrat EP, Vogenberg FR, Principles of Epidemiology for Clinical and Formulary Management Professionals. *P & T* 2006;31(4):218-229

OTHER SCHOLARLY PUBLICATIONS

1. **Dore DD.** A day in the life of a corporate retail pharmacist (Letter in Response to Brock). *Ann Intern Med.* 2014;160(1):70. doi: 10.7326/L14-5000-1
2. Berry SD, **Dore DD.** Understanding drug effects in older people: the role of pharmacology-reply. *JAMA Intern Med.* 2013;173(20):1930-1. doi: 10.1001/jamainternmed.2013.9762
3. **Dore DD,** Norman H, Seeger JD. Eligibility Criteria in Venous Thromboembolism, Myocardial Infarction, and Stroke Among Transdermal Contraceptive System Users. *Obstet Gynecol* 2009;114(1):175.
4. **Dore DD,** Zierler S. Over-Reliance on Patient Information Sheets. *Am J Med* 2007;120(8):e3.

INVITED PRESENTATIONS

1. 2021. Dore DD. "Long-term Care and Geriatric Pharmacoepidemiology." Graduate Seminar, Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research. December 8, 2021. New Brunswick, NJ (via Zoom).
2. 2020. Dore DD. "Large Scale Electronic Health Records Systems in Pharmacoepidemiology – Centralized Systems and Unstructured Data." Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School. May 5, 2020. Boston, MA (via Zoom).
3. 2018. Dore DD. "Big Data and Dementia: Improving Care through Juxtaposition of Disparate Data." World Dementia Council. March 13, 2018. Tokyo, Japan.
4. 2017. Dore DD. "Infrastructure for Pragmatic Trials of Dementia Care." "State of the Science for Pragmatic Trials of Non-Pharmacological Interventions to Improve Outcomes Among Persons with Dementia and Their Caregivers." National Institute on Aging, Bethesda, Maryland
5. 2017. Dore DD. Development and Early Applications of a Large-Scale, Physically Integrated Electronic Health Records Database for Research and Population Health Management. Department of Quantitative Health Sciences, University of Massachusetts Medical School. Worcester, MA
6. 2016. Dore DD (Panelist). "What Can We Learn from Real-world Data – Potential for Data Analytics." Workshop on Real-world Evidence Generation and Evaluation of Therapeutics. National Academies of Science, Engineering, and Medicine (Institute of Medicine). Washington, DC.
7. 2015. Dore DD. "Applying Principles of Observational Research to "Big Data." Novo Nordisk, Copenhagen, Denmark
8. 2015. Dore DD. "Exenatide Use and Risk of Acute Pancreatitis: A Multi-component Drug Safety Assessment Program." Novo Nordisk, Copenhagen, Denmark
9. 2015. Dore DD, Mortimer KM. "Keeping up with "Big Data" in Clinical Development, Drug Safety, and Medical Affairs" Astellas Pharmaceuticals, Chicago, IL

10. 2015. Dore DD. "Research with Electronic Health Records – Epidemiologists Needed for Richer Analyses." Bristol-Myers Squibb, New Brunswick, NJ
11. 2014. Dore DD. "Electronic Health Records, Missing Data, and Causal Inference." Amgen Center for Observational Research, Thousand Oaks, CA.
12. 2013. Dore DD. "Case Studies in Post-marketing Drug Safety Evaluation." Department of Epidemiology, GlaxoSmithKline, Research Triangle Park, NC.
13. 2013. Dore DD. Getting More From Your Trial Data Through Linkage with Administrative Data—A Pharmacoepidemiologist's Perspective. Steering Committee Meeting, NIH Pelvic Floor Disorders Network Meeting, Providence, RI.
14. 2013. Dore DD. A Case-crossover Study of Age-, Gender-, and Dose-Specific Effects on Non-benzodiazepine Hypnotics on the Occurrence of Hip Fracture in Nursing Home Residents. Seminar, Department of Epidemiology, Program in Public Health, Brown University
15. 2012. Dore DD. Research and Scholarship Opportunities in Pharmacoepidemiology. Western New England College of Pharmacy.
16. 2012. Dore DD. The Ortho Evra® Thromboembolism Study and Supplementary Data Collection to Address Bias in Studies using Health Insurance Claims Data. Invited Seminar. Department of Obstetrics and Gynecology, Alpert Medical School/Women and Infants' Hospital. Providence RI.
17. 2011 Dore DD. Exenatide Use and Risk of Acute Pancreatitis: A Multi-study Drug Safety Assessment Program. Invited Seminar. Department of Population Medicine, Harvard Medical School, Boston, MA.
18. 2011 Dore DD. Exenatide Use and Risk of Acute Pancreatitis: A Multi-study Drug Safety Assessment Program. Invited Seminar. Harvard School of Public Health, Boston, MA.
19. 2011 Dore DD. Speaker: Exploring Nontraditional Career Paths, a panel discussion for BioMed Graduate Students and Postdocs featuring PhD's working in industry, entertainment, and government. Brown University.
20. 2011 Dore DD. Use of Commercial Health Insurance Claims Data for Studying HIV/AIDS Care. Testimony to the Institute of Medicine Committee on Data Systems for Monitoring HIV Care. Washington, DC.
21. 2011 Anderson D, Dore DD. Ingenix Natural History of Disease Application—Uses for Pharmacoepidemiology. Seminar in Medical Bioinformatics. Stanford University Medical School, Palo Alto, CA.
22. 2011 Dore DD. Exenatide Use and Risk of Acute Pancreatitis: A Post-marketing Drug Safety Program Involving Safety Signal Refinement, Going Beyond Claims Data, and Mitigating Misclassification Bias and Confounding in a Distributed Data Model. Seminar, Section of Health Services, Policy, and Practice, Department of Community Health, Brown University, Providence, RI